Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Acquires 9,230 Shares

by · The Markets Daily

Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson bought 9,230 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was purchased at an average price of $24.36 per share, with a total value of $224,842.80. Following the completion of the purchase, the chief financial officer directly owned 17,413 shares of the company’s stock, valued at approximately $424,180.68. This trade represents a 112.79% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock traded up $0.54 during midday trading on Wednesday, hitting $24.54. 102,858 shares of the stock were exchanged, compared to its average volume of 189,941. Sensei Biotherapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $36.76. The company has a market capitalization of $32.93 million, a price-to-earnings ratio of -0.17 and a beta of -0.25.

Analyst Upgrades and Downgrades

FTH has been the topic of several recent analyst reports. Weiss Ratings initiated coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. HC Wainwright began coverage on Sensei Biotherapeutics in a research report on Monday. They issued a “buy” rating and a $60.00 target price on the stock. Finally, BTIG Research raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensei Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Check Out Our Latest Analysis on FTH

Key Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

  • Positive Sentiment: HC Wainwright maintained a bullish stance on Sensei Biotherapeutics and reiterated a $60 target, which may have supported investor sentiment despite the company’s expected losses. HC Wainwright analyst report
  • Neutral Sentiment: The firm updated multiple earnings estimates for 2026-2030, forecasting continued losses in the near and medium term, including EPS estimates of ($0.63) for Q2 2026, ($0.69) for Q3 2026, and ($0.75) for Q4 2026. HC Wainwright earnings estimates
  • Neutral Sentiment: HC Wainwright also projected losses for later years, including FY2027 EPS of ($3.72), FY2028 EPS of ($3.19), FY2029 EPS of ($3.16), and FY2030 EPS of ($3.07), reflecting a long path to profitability. HC Wainwright long-term estimates

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.

Further Reading